Helus Pharma
HLP003 · Deuterated Psilocin Analog · Major Depressive Disorder
Company Overview
Helus Pharma (formerly Cybin, rebranded January 5, 2026) is a biopharmaceutical company focused on psychedelic therapeutics. Their lead program HLP003 (formerly CYB003) is a proprietary deuterated psilocin analog — NOT psilocybin — designed for a more predictable duration of action (~4 hours) and improved pharmacokinetics. HLP003 is in the Phase 3 PARADIGM program for Major Depressive Disorder, with the APPROACH pivotal trial as the primary registrational study. Helus is also developing HLP004 (formerly CYB004), a deuterated DMT analog in Phase 2 for Generalized Anxiety Disorder, with topline data expected Q1 2026. Michael Cola was appointed CEO effective February 10, 2026.
Pipeline
| Drug / Compound | Stage | Indication |
|---|---|---|
HLP003 Deuterated psilocin analog (NOT psilocybin) | Phase 3 | Major Depressive Disorder |
HLP004 Deuterated DMT analog | Phase 2 | Generalized Anxiety Disorder |
Key Financials
- Cash Position
- $195.1M
- Burn Rate
- ~$32-37M/quarter
- Last Reported
- Q3 2025
Financial data is approximate. Always verify with official SEC filings.
Upcoming Catalysts
- Q1 2026HLP004 Phase 2 topline data readout in Generalized Anxiety DisorderClinical
- Q4 2026APPROACH pivotal trial topline data for HLP003 in MDDClinical
Recent News
- 2026-02Michael Cola appointed CEO of Helus Pharma, effective February 10, 2026
- 2026-01Cybin rebrands as Helus Pharma, trades on Nasdaq as HELP; HLP003 Phase 3 PARADIGM program underway; CYB003/CYB004 renamed HLP003/HLP004
News items are manually curated from public company press releases.
External Links
Looking for psychedelic therapy?
Browse our directory of 700+ verified ketamine and psychedelic therapy clinics across 49 states. Find providers near you who offer ketamine and psychedelic-assisted therapy.
Disclaimer: This page is for informational purposes only and does not constitute investment, medical, or financial advice. Pipeline status, financial figures, and catalyst dates are approximate and based on publicly available information as of 2026-02-25. Always consult official company filings and a qualified financial advisor before making investment decisions.